Patents by Inventor Abdelmalik Slassi

Abdelmalik Slassi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20240051978
    Abstract: The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, and treating diseases, disorders or conditions treatable by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis and mental illness.
    Type: Application
    Filed: December 7, 2021
    Publication date: February 15, 2024
    Applicant: Mindset Pharma Inc.
    Inventors: Abdelmalik Slassi, Joseph Araujo, Guy Higgins
  • SCALABLE SYNTHETIC ROUTE FOR PSILOCIN AND PSILOCYBIN
    Publication number: 20230286916
    Abstract: The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.
    Type: Application
    Filed: July 23, 2021
    Publication date: September 14, 2023
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20230203070
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: February 15, 2023
    Publication date: June 29, 2023
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20230167141
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 1, 2023
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20230118872
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 20, 2023
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20230105399
    Abstract: The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.
    Type: Application
    Filed: August 2, 2022
    Publication date: April 6, 2023
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
    Patent number: 11597738
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: March 7, 2023
    Assignee: MINDSET PHARMA INC.
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
    Patent number: 11591353
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: February 28, 2023
    Assignee: Mindset Pharma Inc.
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20220324889
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: June 6, 2022
    Publication date: October 13, 2022
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
    Patent number: 11453689
    Abstract: The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: September 27, 2022
    Assignee: MINDSET PHARMA INC.
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20220289774
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 15, 2022
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
    Patent number: 11427604
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: August 30, 2022
    Assignee: Mindset Pharma Inc.
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20220024956
    Abstract: The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 27, 2022
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20220017549
    Abstract: The present application relates to psilocin derivatives of Formula (1), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 20, 2022
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20220017550
    Abstract: The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 20, 2022
    Inventors: Abdelmalik Slassi, Joseph Araujo
  • Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
    Patent number: 10696670
    Abstract: A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS
    Publication number: 20200181067
    Abstract: The present application relates to novel fluorinated amide derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and memory deficits, as well as chronic and acute pain and other related CNS disorders.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: Trillium Therapeutics Inc.
    Inventor: Abdelmalik Slassi
  • Fluorinated amide derivatives and their uses as therapeutic agents
    Patent number: 10604476
    Abstract: The present application relates to novel fluorinated amide derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and memory deficits, as well as chronic and acute pain and other related CNS disorders.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 31, 2020
    Assignee: Trillium Therapeutics Inc.
    Inventor: Abdelmalik Slassi
  • HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS
    Publication number: 20200031825
    Abstract: Compounds of Formula I and II have been prepared for use in the treatment of diseases, disorders or conditions treatable by activation of the stimulator of interferon genes (STING) adaptor protein, such as in the treatment or prevention of cancers.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 30, 2020
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter DOVE, Zezhou WANG, Hoi Ying LIN, David Alexander ROSA, Jeffrey Todd WINSTON
  • HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
    Publication number: 20190367466
    Abstract: The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and/or memory deficits, as well as chronic and acute pain and other related CNS disorders.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 5, 2019
    Applicant: Trillium Therapeutics Inc.
    Inventor: Abdelmalik Slassi